<![CDATA[Background: Coronavirus Disease 2019 (Covid-19) is an infectious disease. Common signs and symptoms of Covid-19 infection include acute respiratory distress such as fever, cough and shortness of breath. Analysis of drug use in Non-Ventilator Covid-19 patients needs to be carried out to provide an overview of drug therapy currently being used based on the Covid-19 Management Guidelines Edition 3rd because so far, there has not been a single type of drug that has received marketing authorization for Covid-19 therapy. Objectives: This study aims to determine patient profiles, therapeutic outcomes, suitability of drug use with Covid-19 Management Guidelines 3rd edition, the quantity of antibiotic use using the DDD/100 patient-days method and antivirals. Methods: The method used in this study is an observational design study which was analyzed descriptively with retrospective data collection. Result: Based on the profile of drug use in COVID-19 patients, there are 31 types of drug classes. The most consumed drugs were antibacterial (91%) and analgesics (91%), followed by vitamins (89%) and supplements (85%). Based on the DDD/100 patient-days value, the most widely used antibiotics were Azithromycin. Conclusion: The patient's profile at the time of admission to the hospital was 44% moderate and 56% severe. The condition of patients at the time of discharge from the hospital with a moderate degree using antivirals and antibiotics were more recovered and returned home with improvements with percentages of 84.1% and 88.64%, respectively.]]>
Copyrights © 2022
